ArticleDiscover oncology2025
Identifying putative causal links between serum circulating microRNAs and thyroid cancer using Mendelian randomization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer, the most common malignancy in the endocrine system, has seen a global increase in incidence. This study aims to investigate the causal relationship between serum circulating microRNAs (miRNAs) and thyroid cancer risk using a Mendelian randomization (MR) approach.
methodsWe conducted a two-sample MR analysis using miRNA expression quantitative trait loci (eQTL) data from two independent cohorts and thyroid cancer genome-wide association study (GWAS) data. The discovery cohort included miRNA expression levels quantified via qRT-PCR in whole blood samples, while the validation cohort comprised miRNA expression data from blood samples of unrelated individuals of European ancestry. We applied various MR methods, including inverse variance-weighted (IVW) and MR-Egger, to assess the genetic associations between miRNAs and thyroid cancer. Additionally, we performed target gene prediction and pathway analysis to explore the biological mechanisms underlying the observed associations.
resultsOur analysis identified three miRNAs significantly associated with thyroid cancer risk: miR-hsa-125b-5p and miR-hsa-30a-3p were found to have harmful effects, while miR-hsa-130a-3p exhibited a protective effect. These findings were consistently validated across both cohorts. The target genes of these miRNAs were enriched in pathways related to gland development, myeloid cell differentiation, cellular senescence, FoxO signaling pathway, and p53 signaling pathway, providing insights into the potential molecular mechanisms linking these miRNAs to thyroid cancer.
conclusionThis study suggests potential causal associations between specific serum circulating miRNAs and thyroid cancer risk using a Mendelian randomization approach. The identified miRNAs, including miR-hsa-125b-5p, miR-hsa-30a-3p, and miR-hsa-130a-3p, could be further investigated as potential biomarkers for risk prediction and early diagnosis of thyroid cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.